Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma

Oclacitinib and Myxoma Virus Therapy in Dogs with High-Grade Soft Tissue Sarcoma

Human rhabdomyosarcomas are rarely cured by surgical resection alone. This is also true for high-grade soft tissue sarcomas in dogs. Dogs with spontaneous sarcoma are good models for clinical responses to new cancer therapies. Strategic combinations of immunotherapy and oncolytic virotherapy (OV) co...

Full description

Bibliographic Details
Main Authors:	Laura V. Ashton, Kristen M. Weishaar, Bernard Séguin, Amy L. MacNeill
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Series:	Biomedicines
Subjects:	cytokines oclacitinib oncolytic virus dogs cancer
Online Access:	https://www.mdpi.com/2227-9059/11/9/2346

Similar Items

Diminished antimicrobial drug use in dogs with allergic dermatitis treated with oclacitinib
by: Kennedy Mwacalimba, et al.
Published: (2023-09-01)

The Association Between the Use of Oclacitinib and Antibacterial Therapy in Dogs With Allergic Dermatitis: A Retrospective Case-Control Study
by: Hester Rynhoud, et al.
Published: (2021-02-01)

Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis
by: Marike Visser, et al.
Published: (2022-03-01)

Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study
by: Laura E. Barrett, et al.
Published: (2019-08-01)

Complete remission of two canine cases with precursor-targeted immune-mediated anemia after combination therapy with prednisolone, cyclosporine, and oclacitinib
by: Masashi Yuki, et al.
Published: (2023-09-01)

Development and validation of an UV-Vis spectrophotometric method for the quantification of oclacitinib in capsule formulation
by: Danilo R. O. Momade, et al.
Published: (2021-02-01)

A blinded, randomized, placebo-controlled trial of the safety of oclacitinib in cats
by: Natália Lôres Lopes, et al.
Published: (2019-05-01)

The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
by: Hester Rynhoud, et al.
Published: (2022-04-01)

Dog Owners’ Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey
by: Andrea Wright, et al.
Published: (2024-03-01)

In dogs with atopic skin disease, is lokivetmab more effective than oclacitinib in reducing the score of a recognised scoring system?
by: Bonnie Yuan Tone Cheung
Published: (2022-06-01)

Recombinant Myxoma Virus Expressing Walleye Dermal Sarcoma Virus orfC Is Attenuated in Rabbits
by: Laura V. Ashton, et al.
Published: (2020-05-01)

Oclacitinib, a Janus Kinase Inhibitor, Reduces the Frequency of IL-4- and IL-10-, but Not IFN-γ-, Producing Murine CD4<sup>+</sup> and CD8<sup>+</sup> T Cells and Counteracts the Induction of Type 1 Regulatory T Cells
by: Agnieszka Jasiecka-Mikołajczyk, et al.
Published: (2021-09-01)

Diffuse cutaneous mastocytosis (pigmented maculopapular cutaneous mastocytosis) in a cat
by: Marcin Szczepanik, et al.
Published: (2020-03-01)

Canine Soft Tissue Sarcomas: Can Being a Dog’s Best Friend Help a Child?
by: Bernard Séguin
Published: (2017-11-01)

Establishment of an Intradermal Canine IL-31-Induced Pruritus Model to Evaluate Therapeutic Candidates in Atopic Dermatitis
by: Jason Pearson, et al.
Published: (2023-05-01)

Inibidores das Janus Associated Kinases na Terapêutica Farmacológica
by: Manuel Morgado, et al.
Published: (2017-04-01)

Janus Associated Kinases Inhibitors in the Pharmacological Thera
by: Daniela Santos1, et al.
Published: (2017-01-01)

Systemic Delivery of mLIGHT-Armed Myxoma Virus Is Therapeutic for Later-Stage Syngeneic Murine Lung Metastatic Osteosarcoma
by: John D. Christie, et al.
Published: (2022-01-01)

Myxoma in a Terrier Dog: A Case Report
by: Amin Derakhshanfar, et al.
Published: (2007-03-01)

Assessing a Novel 3D Assay System for Drug Screening against OS Metastasis
by: Natalie Koons, et al.
Published: (2021-09-01)

Decreasing the Susceptibility of Malignant Cells to Infection Does Not Impact the Overall Efficacy of Myxoma Virus-Based Oncolytic Virotherapy
by: Erica B. Flores, et al.
Published: (2020-12-01)

Dogs with osteosarcoma have altered pro‐ and anti‐inflammatory cytokine profiles
by: Sandra M. Axiak‐Bechtel, et al.
Published: (2019-11-01)

Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy
by: Hiroshi Tazawa, et al.
Published: (2020-02-01)

Myxoma Virus Combination Therapy Enhances Lenalidomide and Bortezomib Treatments for Multiple Myeloma
by: Alpay Yeşilaltay, et al.
Published: (2024-01-01)

Better food for dogs : a complete cookbook and nutrition guide /
by: 192128 Bastin, David, et al.
Published: (2002)

Immunotherapeutic Potential of Oncolytic Vaccinia Virus
by: Stephen eThorne
Published: (2014-06-01)

Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
by: Joanna Jazowiecka-Rakus, et al.
Published: (2020-09-01)

Oncolytic virotherapy with intratumoral injection of vaccinia virus TG6002 and 5-fluorocytosine administration in dogs with malignant tumors
by: Jérémy Béguin, et al.
Published: (2023-09-01)

Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
by: Joanna Jazowiecka-Rakus, et al.
Published: (2022-04-01)

Investigation of Some Cytokines, Acute Phase Proteins and Hepcidin Levels Before and After Treatment in Dogs with Parvoviral Gastroenteritis
by: Sima Sahinduran1*, Metin Koray Albay1, Mehmet Cagri Karakurum1, Ozlem Ozmen2 and Mehmet Kale3
Published: (2016-11-01)

The Complete DOG OWNER'S MANUAL /
by: Marder, Amy, author 644275
Published: (1997)

Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
by: Joanna Jazowiecka-Rakus, et al.
Published: (2021-03-01)

Neutrophil Myeloperoxidase Index in Dogs With Babesiosis Caused by Babesia rossi
by: Anri Celliers, et al.
Published: (2020-02-01)

Multi-modal efficacy of a chimeric vesiculovirus expressing the Morreton glycoprotein in sarcoma
by: Chelsae R. Watters, et al.
Published: (2023-06-01)

Non-invasive evaluation of cytokine expression using the cerumen of dogs with otitis externa
by: Ji-Seon Yoon, et al.
Published: (2024-02-01)

Oncolytic Viral Therapy for Glioma by Recombinant Sindbis Virus
by: Kangyixin Sun, et al.
Published: (2023-09-01)

Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges
by: Shyambabu Chaurasiya, et al.
Published: (2020-06-01)

Comparison of serum 25(OH) vitamin D, parathormone and immunity marker concentrations between dogs with transmissible venereal tumour and healthy dogs
by: Helia Kamali Sadeghian, et al.
Published: (2023-09-01)

The One Health Consortium: Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Combination With a Checkpoint Inhibitor in Canine Patients With Sporadic High Grade Gliomas
by: M. R. Chambers, et al.
Published: (2020-08-01)

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma
by: Maud Toulmonde, et al.
Published: (2022-10-01)